• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 中的补体激活及靶向治疗选择:范围综述。

Complement activation in COVID-19 and targeted therapeutic options: A scoping review.

机构信息

Amsterdam UMC location University of Amsterdam, Department of Intensive Care Medicine, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Laboratory of Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Amsterdam, the Netherlands; Amsterdam UMC location University of Amsterdam, Department of Neurology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Neuroscience, Amsterdam, the Netherlands.

Amsterdam UMC location University of Amsterdam, Department of Intensive Care Medicine, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Laboratory of Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Amsterdam, the Netherlands.

出版信息

Blood Rev. 2023 Jan;57:100995. doi: 10.1016/j.blre.2022.100995. Epub 2022 Jul 30.

DOI:10.1016/j.blre.2022.100995
PMID:35934552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9338830/
Abstract

Increasing evidence suggests that activation of the complement system plays a key role in the pathogenesis and disease severity of Coronavirus disease 2019 (COVID-19). We used a systematic approach to create an overview of complement activation in COVID-19 based on histopathological, preclinical, multiomics, observational and clinical interventional studies. A total of 1801 articles from PubMed, EMBASE and Cochrane was screened of which 157 articles were included in this scoping review. Histopathological, preclinical, multiomics and observational studies showed apparent complement activation through all three complement pathways and a correlation with disease severity and mortality. The complement system was targeted at different levels in COVID-19, of which C5 and C5a inhibition seem most promising. Adequately powered, double blind RCTs are necessary in order to further investigate the effect of targeting the complement system in COVID-19.

摘要

越来越多的证据表明,补体系统的激活在 2019 年冠状病毒病(COVID-19)的发病机制和疾病严重程度中起着关键作用。我们使用系统的方法,根据组织病理学、临床前、多组学、观察性和临床干预研究,对 COVID-19 中的补体激活进行概述。从 PubMed、EMBASE 和 Cochrane 筛选了 1801 篇文章,其中 157 篇文章被纳入本范围综述。组织病理学、临床前、多组学和观察性研究表明,通过所有三种补体途径都明显存在补体激活,并与疾病严重程度和死亡率相关。补体系统在 COVID-19 中靶向不同的水平,其中 C5 和 C5a 的抑制似乎最有希望。为了进一步研究靶向 COVID-19 补体系统的效果,有必要进行充分的、双盲的 RCT。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7332/9338830/e55b9673e6dc/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7332/9338830/98478f62db82/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7332/9338830/e55b9673e6dc/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7332/9338830/98478f62db82/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7332/9338830/e55b9673e6dc/gr2_lrg.jpg

相似文献

1
Complement activation in COVID-19 and targeted therapeutic options: A scoping review.COVID-19 中的补体激活及靶向治疗选择:范围综述。
Blood Rev. 2023 Jan;57:100995. doi: 10.1016/j.blre.2022.100995. Epub 2022 Jul 30.
2
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.补体 C3 与 C5 抑制在重症 COVID-19 中的作用:早期临床发现揭示了不同的生物学疗效。
Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19.
3
Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.补体过度激活和消耗可预测 SARS-CoV-2 感染患者的住院死亡率。
Front Immunol. 2021 Mar 25;12:663187. doi: 10.3389/fimmu.2021.663187. eCollection 2021.
4
Hyper-inflammation and complement in COVID-19.COVID-19 中的过度炎症与补体
Am J Hematol. 2023 May;98 Suppl 4:S74-S81. doi: 10.1002/ajh.26746.
5
Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.凝集素途径介导严重急性呼吸综合征冠状病毒2(SARS-CoV-2)蛋白激活补体。
Front Immunol. 2021 Jul 5;12:714511. doi: 10.3389/fimmu.2021.714511. eCollection 2021.
6
Remdesivir for the treatment of COVID-19.瑞德西韦用于治疗新型冠状病毒肺炎。
Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.
7
The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy.C5a 在 COVID-19 相关凝血功能障碍发病机制中的作用及潜在治疗意义。
Cytokine Growth Factor Rev. 2021 Apr;58:75-81. doi: 10.1016/j.cytogfr.2020.12.001. Epub 2020 Dec 13.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
Complement cascade in severe forms of COVID-19: Recent advances in therapy.补体级联反应在 COVID-19 严重形式中的作用:治疗的最新进展。
Eur J Immunol. 2021 Jul;51(7):1652-1659. doi: 10.1002/eji.202048959. Epub 2021 Apr 10.
10
The case of complement activation in COVID-19 multiorgan impact.新型冠状病毒肺炎多器官损伤中补体激活的病例。
Kidney Int. 2020 Aug;98(2):314-322. doi: 10.1016/j.kint.2020.05.013. Epub 2020 May 24.

引用本文的文献

1
Treatment with intravenous immunoglobulin modulates coagulation- and complement-related pathways in COVID-19 patients.静脉注射免疫球蛋白治疗可调节新冠肺炎患者的凝血和补体相关途径。
Front Immunol. 2025 Jul 31;16:1623309. doi: 10.3389/fimmu.2025.1623309. eCollection 2025.
2
MICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury.MICBG406A基因多态性降低了病毒性急性肺损伤期间机械通气和死亡的风险。
JCI Insight. 2025 Jul 3;10(15). doi: 10.1172/jci.insight.191951. eCollection 2025 Aug 8.
3
A percolation phase transition controls complement protein coating of surfaces.
渗流相变控制表面的补体蛋白包被。
Cell. 2025 Jun 12. doi: 10.1016/j.cell.2025.05.026.
4
Antibody-dependent enhancement of SARS-CoV-2, the impact of variants and vaccination.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗体依赖性增强作用、变异株及疫苗接种的影响
Hum Vaccin Immunother. 2025 Dec;21(1):2505356. doi: 10.1080/21645515.2025.2505356. Epub 2025 May 24.
5
Impact of SARS-CoV-2 Wuhan and Omicron Variant Proteins on Type I Interferon Response.严重急性呼吸综合征冠状病毒2型武汉株和奥密克戎变异株蛋白对I型干扰素反应的影响。
Viruses. 2025 Apr 15;17(4):569. doi: 10.3390/v17040569.
6
Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease, and Platform-Inherent Challenges.与新冠基因疫苗相关的不良事件的谱扩大及发生率增加:预防性免疫基因治疗、医源性罕见病和平台固有挑战的新概念
Pharmaceutics. 2025 Mar 31;17(4):450. doi: 10.3390/pharmaceutics17040450.
7
Exploring the biological mechanisms of severe COVID-19 in the elderly: Insights from an aged mouse model.探索老年人中重症新型冠状病毒肺炎的生物学机制:来自老年小鼠模型的见解
Virulence. 2025 Dec;16(1):2487671. doi: 10.1080/21505594.2025.2487671. Epub 2025 Apr 14.
8
Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination-Associated Thrombotic Microangiopathy.个体患者数据的系统评价:COVID-19感染与疫苗接种相关的血栓性微血管病
Kidney Int Rep. 2024 Aug 8;9(11):3134-3144. doi: 10.1016/j.ekir.2024.07.034. eCollection 2024 Nov.
9
Immunopathological markers and cell types linked to COVID-19 symptom manifestation.与 COVID-19 症状表现相关的免疫病理标志物和细胞类型。
BMC Infect Dis. 2024 Nov 4;24(1):1237. doi: 10.1186/s12879-024-10139-z.
10
Immunity and Coagulation in COVID-19.新型冠状病毒肺炎中的免疫与凝血。
Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267.